October 19, 2011
INVESTIGATIONAL LAQUINIMOD DEMONSTRATES ITS POTENTIAL AS A NEW ORAL TREATMENT FOR RRMS
- /
Wed Oct 19, 2011 2:30am EDT Late-breaking presentation of BRAVO results and additional analyses from ALLEGRO study reinforce novel clinical…
MS Views and News, empowers those affected by Multiple Sclerosis (MS) with educational information, resources and services. Please scroll downward to find articles or videos of interest, then click to open the document or video.
October 19, 2011
Nutra Pharma Receives Patent for Their Multiple Sclerosis Drug
- /
Nutra Pharma has been issued a patent by the U.S. Patent and Trademark Office that protects their therapy for Multiple…
October 19, 2011
Multiple Sclerosis Research Roundup October 2011
- /
Funky Mango has very kindly let us repost her Ovtober round up of multiple sclerosis research! Funky Mango blogs at http://funkymangosmusings.blogspot.com/ so…
October 19, 2011
Real Talk Real Answers free iPhone® application
- /
MS LifeLines® and the National Multiple Sclerosis Society are announcing the addition of new videos to the Real Talk Real…
October 19, 2011
How to dissolve fear when you have a chronic illness
- /
- /
From Karen Gordon – the Self Healing Coach Just a quick note to let you know that I just published…
October 18, 2011
Genzyme is committed to transforming the landscape of MS treatment
- /
- /
- /
PARIS, Oct 18, 2011 (BUSINESS WIRE) — Sanofi and its subsidiary Genzyme announced today that more than 20 data presentations…
October 18, 2011
If you had one chance to prevent MS, what would you do?
- /
- /
This is the very question which Ryan McLaughlin from Glasgow, Scotland has the answer to. Ryan McLaughlin is only to well…
October 18, 2011
Currently AVAILABLE Therapies for Relapsing forms of Multiple Sclerosis
- /
- /
Approved therapies to treat RRMS COPAXONE®: A unique RRMS therapy thought to modify the immune response by helping to restore…
October 17, 2011
Novartis drug Gilenya® (fingolimod) has more than 20,000 patient-years of exposure and shows up to 71% reduction in annualized relapse rates in MS patients with highly active disease
- /
Mon Oct 17, 2011 1:15am EDT Novartis International AG / Novartis drug Gilenya® (fingolimod) has more than 20,000 patient-years of…
October 17, 2011
Shift Work / Night Work, May Put Teens at Risk for Multiple Sclerosis
- /
- /
MONDAY, Oct. 17 (HealthDay News) — Working overnight or odd shifts may increase teenagers’ risk of developing multiple sclerosis, according to…
